Henry Schein Inc

Henry Schein’s modest insider sale shows routine portfolio‑rebalance, not distress—backed by solid fundamentals, tech‑driven supply‑chain gains, and value‑based care momentum.

Analyze Henry Schein’s March 2026 insider trades: a rapid buy‑sell by Kuehn Kurt P shows routine liquidity moves, while executive buying signals confidence and robust fundamentals.

KKR’s 918k‑share equity swap shows bullish confidence in Henry Schein; insiders’ buying, growth prospects, and a solid distribution network suggest potential upside for investors.

KKR Hawaii’s latest equity‑swap on Henry Schein shows confidence in growth, giving investors a low‑cost, risk‑managed way to benefit from the company’s dental‑healthcare expansion.

CEO’s 53k‑share RSU buy shows confidence in Henry Schein’s near‑term prospects—an insider signal amid strong fundamentals, steady cash flow, and a key role in medical‑research supply chains.

CEO insider buys 64k shares & options – a bullish signal for Henry Schein’s value‑based health‑care strategy, solid valuation, and growth prospects.

Henry Schein’s CEO receives a 30,723‑unit RSU grant—showing board confidence, aligning incentives, and signaling steady growth amid insider sales and health‑care tech trends.

Henry Schein CFO and top execs sell shares after earnings; investors weigh insider selling as possible sign of strategic shift or personal liquidity, but fundamentals stay strong.

Henry Schein insider moves signal a strategic shift to tech‑driven growth: CEO holds, chairman sells, KKR equity swaps boost capital for expansion and innovation.

Henry Schein CEO’s modest insider sales after an earnings beat—why a 0.4 % sell‑off signals confidence, not panic, in a growing dental‑healthcare firm.